Electrochemical bioassay development for ultrasensitive aptasensing of prostate specific antigen.
A densely packed gold nanoparticles on the rGO-MWCNT platform was used as the basis for an ultrasensitive label-free electrochemical aptasensor to detect the biomarker prostate specific antigen (PSA) in serum. The detection was based on that the variation of electron transfer resistance (Rct) and differential pulse voltammetry (DPV) current were relevant to the formation of PSA-aptamer complex at the modified electrode surface. Compared with pure AuNPs, rGO-MWCNT and MWCNT/AuNPs, the rGO-MWCNT/AuNPs nanocomposite modified electrode was the most sensitive aptasensing platform for the determination of PSA. Two calibration curves were prepared from the data obtained from the DPV and electrochemical impedance spectroscopy (EIS) by plotting the peak current and Rct against PSA concentration, respectively. The proposed aptasensor had an extremely low LOD of 1.0pgmL-1 PSA within the detection range of 0.005-20ngmL-1 and 0.005-100ngmL-1 for DPV and EIS calibration curves, respectively. This sensor exhibited outstanding anti-interference ability towards co-existing molecules with good stability, sensitivity, and reproducibility. Clinical application was performed with analysis of the PSA levels in serum samples obtained from patients with prostate cancer using both the aptasensor and Immunoradiometric assay. The results revealed the proposed system to be a promising candidate for clinical analysis of PSA.